Click the link to read the press release in French.
TORONTO, ON – May 21, 2026 —For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
By testing new strategies to prevent, detect, treat and care for people affected by cancer, clinical trials are essential to driving research progress that can save and improve lives. The LUNA-2 trial will pair immunotherapy with fecal microbiota transplantation (FMT) with the goal of safely increasing treatment effectiveness. If successful, it could provide new treatment options for people with lung cancer, helping them live longer and with fewer side effects.
Lung cancer is the most commonly diagnosed cancer in Canada and the leading cause of cancer death. Currently, only about 27% of people survive longer than 5 years after diagnosis. Although immunotherapy is an important part of lung cancer treatment, it doesn’t work for everyone. For these people, enhancing the effectiveness of immunotherapy could have a profound and life-saving impact.
By supporting bold, high-risk research, the Foundation creates space for Canadian researchers to tackle urgent health challenges, evaluate new paradigms, and improve lives.
For more information, please refer to the links below: